AUTHOR=Mao WeiLi , Lu Peng , Wan Renhong , Mao Kaili , Lv Yanzhu , Hu Jie , Fu Zhenling , Wang Jun 

TITLE=Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1100006

DOI=10.3389/fcvm.2023.1100006

ISSN=2297-055X

ABSTRACT=Background: Danlou tablet exerts auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based evidence is lacking. This study is to systematically evaluate Danlou tablet in treating CHD from two aspects, including effectiveness and safety. Methods: Through thorough retrieval of four English databases: PubMed, The Cochrane Library, Embase, Web of Science, and four Chinese databases: CNKI, Wanfang, VIP database and China Biomedical Literature Service System (CBM), we found all randomized controlled trials (RCTs) related to Danlou tablets in treating CHD. The retrieval time was from the database construction to April 2022. We dispatched two researchers to screen the studies, extract required data and assess the risk of bias, then, we used RevMan5.3 and STATA.14 software to conduct meta-analysis. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to evaluate the quality of outcome indicators. Results: 17 RCTs involving 1588 patients were included. The Meta-analysis results displayed: Clinical Treatment effect [RR=1.22, 95%CI: 1.16, 1.28, P<0.00001], Angina Pectoris Duration [MD=-0.2.15, 95%CI: -2.91, -1.04, P<0.00001], Angina Pectoris Frequency [SMD=-2.48, 95%CI: -3.42, -1.54, P<0.00001], Angina Pectoris Degree [SMD=-0.96, 95%CI: -1.39, -0.53, P<0.0001], TC [MD=-0.71, 95%CI: -0.92, -0.51, P<0.00001], TG [MD=-0.38, 95%CI: -0.53, -0.22, P<0.00001], LDL-C [MD=-0.64, 95%CI: -0.76, -0.51, P<0.00001], HDL-C [MD=0.16, 95%CI: 0.11, 0.21, P<0.00001]; Adverse events [RR=0.46, 95%CI: 0.24, 0.88, P=0.02]. Conclusion: The current evidence suggests that the combination of Danlou tablet and western medicine can enhance the efficacy of CHD, and do not increase adverse events. However, for the reason of the limited number and quality of the included studies, results in our study should be treated with caution. Further large-scale RCTs are necessary to verify the benefits of this approach.